Thompson Siegel & Walmsley LLC grew its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 10.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 565,337 shares of the company's stock after acquiring an additional 51,705 shares during the quarter. Thompson Siegel & Walmsley LLC owned about 0.08% of Roivant Sciences worth $6,688,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the stock. FMR LLC increased its stake in Roivant Sciences by 5.6% during the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company's stock valued at $567,134,000 after purchasing an additional 2,593,910 shares in the last quarter. State Street Corp grew its holdings in shares of Roivant Sciences by 6.1% during the third quarter. State Street Corp now owns 19,561,249 shares of the company's stock valued at $225,737,000 after buying an additional 1,118,561 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Roivant Sciences by 23.2% during the third quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company's stock valued at $89,400,000 after acquiring an additional 1,460,205 shares in the last quarter. TOMS Capital Investment Management LP purchased a new position in Roivant Sciences in the 3rd quarter worth approximately $46,333,000. Finally, Loomis Sayles & Co. L P lifted its position in Roivant Sciences by 13.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company's stock valued at $45,147,000 after acquiring an additional 458,601 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.
Roivant Sciences Stock Up 1.8 %
ROIV stock traded up $0.19 during midday trading on Monday, hitting $10.85. The company's stock had a trading volume of 5,225,228 shares, compared to its average volume of 5,484,257. Roivant Sciences Ltd. has a 12 month low of $9.76 and a 12 month high of $13.06. The company has a 50 day moving average of $10.80 and a two-hundred day moving average of $11.49. The firm has a market capitalization of $7.74 billion, a price-to-earnings ratio of -72.33 and a beta of 1.26.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.
Insider Activity
In other Roivant Sciences news, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the firm's stock in a transaction that occurred on Monday, January 13th. The shares were bought at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the purchase, the director now directly owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now directly owns 163,264 shares of the company's stock, valued at $1,702,843.52. The trade was a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,388,170 shares of company stock worth $27,612,299 over the last 90 days. Corporate insiders own 7.90% of the company's stock.
Analyst Ratings Changes
ROIV has been the topic of several analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $18.08.
Get Our Latest Research Report on Roivant Sciences
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
